New cancer clinical trial: Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Published on: December 27, 2018 at 12:00PM
Condition:   Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Interventions:   Drug: Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo;   Drug: Placebo Gefitinib 250 mg;   Drug: Gefitinib 250 mg;   Drug: Placebo AST2818 80mg//40 mg
Sponsor:   Allist Pharmaceuticals, Inc.
Not yet recruiting
http://bit.ly/2BO5ZAL